As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that ...

Medically reviewed by Marla Anderson, MD If you have HER2-positive breast cancer, your options for treatment will depend on ...

Kadcyla is a next generation breast cancer drug, where a cancer-killing cytotoxic agent, emtansine has been added to the monoclonal antibody, trastuzumab – the active ingredient in Roche’s ...